KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Accumulated Expenses: 2010-2025

Historic Other Accumulated Expenses for TherapeuticsMD (TXMD) over the last 7 years, with Sep 2025 value amounting to $301,000.

  • TherapeuticsMD's Other Accumulated Expenses was N/A to $301,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $301,000, marking a year-over-year change of. This contributed to the annual value of $88,000 for FY2024, which is 78.48% down from last year.
  • As of Q3 2025, TherapeuticsMD's Other Accumulated Expenses stood at $301,000, which was up 49.01% from $202,000 recorded in Q2 2025.
  • TherapeuticsMD's 5-year Other Accumulated Expenses high stood at $59.2 million for Q2 2022, and its period low was $88,000 during Q4 2024.
  • Over the past 3 years, TherapeuticsMD's median Other Accumulated Expenses value was $355,000 (recorded in 2023), while the average stood at $4.3 million.
  • Per our database at Business Quant, TherapeuticsMD's Other Accumulated Expenses soared by 580.86% in 2021 and then slumped by 97.83% in 2023.
  • Over the past 5 years, TherapeuticsMD's Other Accumulated Expenses (Quarterly) stood at $13.3 million in 2021, then soared by 41.30% to $18.8 million in 2022, then crashed by 97.83% to $409,000 in 2023, then crashed by 78.48% to $88,000 in 2024, then reached $301,000 in 2025.
  • Its Other Accumulated Expenses stands at $301,000 for Q3 2025, versus $202,000 for Q2 2025 and $249,000 for Q1 2025.